PepGen Inc.

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

With a US Food and Drug Administration partial clinical hold lifted, Avidity Biosciences, Inc. is moving forward with a Phase III trial of its antibody-oligonucleotide conjugate (AOC) candidate delp

Third Harmonic Bio launched an initial public offering on 14 September that marked the first IPO in the US by a biopharmaceutical company in four months to raise more than $100m. In fact, the last th

Third Harmonic Bio Inc. could be the first biopharmaceutical company to launch an initial public offering in the US since the end of July and deliver the first biopharma IPO to raise more than $100m